FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067888950> ?p ?o ?g. }

• W2067888950 endingPage "1011" @default.
• W2067888950 startingPage "1006" @default.
• W2067888950 abstract "We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamics and safety of entacapone and apomorphine coadministration in these patients were examined. The study followed a three-sequence, three-period, crossover design. Patients were randomly assigned to one of three sequences that included single oral doses of entacapone 200 mg, entacapone 400 mg, and placebo in a predefined order. On 3 separate test days, study treatment was administered before apomorphine. The study evaluations (pharmacokinetics, tapping test, and dyskinesia evaluation [Abnormal Involuntary Movements Scale - AIMS]) were performed on these days. Furthermore, Unified Parkinson Disease Rating Scale (UPDRS) scores were evaluated at baseline and study end. Pharmacokinetic parameters for apomorphine (C(max), AUC, t(max), t(1/2)) were unchanged by the administration of entacapone, and changes in both the tapping test and AIMS score were similar with all treatments (entacapone 200 mg, entacapone 400 mg, and placebo). There was no significant difference in mean total UPDRS scores between baseline and study end. The administration of entacapone did not change the pharmacokinetic or pharmacodynamic effects of apomorphine in these patients or prolong the clinical effect of apomorphine. Thus, apomorphine may be safely administered to patients receiving therapy with levodopa and entacapone, providing a useful addition to treatment for patients with advanced Parkinson's disease." @default.
• W2067888950 created "2016-06-24" @default.
• W2067888950 creator A5023680900 @default.
• W2067888950 creator A5043835524 @default.
• W2067888950 creator A5054027214 @default.
• W2067888950 creator A5063335320 @default.
• W2067888950 creator A5078352037 @default.
• W2067888950 date "2004-09-01" @default.
• W2067888950 modified "2023-10-03" @default.
• W2067888950 title "Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study" @default.
• W2067888950 cites W1964638035 @default.
• W2067888950 cites W1977677585 @default.
• W2067888950 cites W1978896355 @default.
• W2067888950 cites W1980275041 @default.
• W2067888950 cites W1983046432 @default.
• W2067888950 cites W1984593979 @default.
• W2067888950 cites W1984671881 @default.
• W2067888950 cites W1984702297 @default.
• W2067888950 cites W1992401185 @default.
• W2067888950 cites W2008043188 @default.
• W2067888950 cites W2012060986 @default.
• W2067888950 cites W2017055459 @default.
• W2067888950 cites W2024440004 @default.
• W2067888950 cites W2053851028 @default.
• W2067888950 cites W2059456726 @default.
• W2067888950 cites W2071608414 @default.
• W2067888950 cites W2075895531 @default.
• W2067888950 cites W2076281963 @default.
• W2067888950 cites W2084669272 @default.
• W2067888950 cites W2132528735 @default.
• W2067888950 cites W2163222423 @default.
• W2067888950 cites W2171570158 @default.
• W2067888950 cites W224924917 @default.
• W2067888950 cites W23294186 @default.
• W2067888950 cites W4206634583 @default.
• W2067888950 doi "https://doi.org/10.1002/mds.20188" @default.
• W2067888950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15372589" @default.
• W2067888950 hasPublicationYear "2004" @default.
• W2067888950 type Work @default.
• W2067888950 sameAs 2067888950 @default.
• W2067888950 citedByCount "13" @default.
• W2067888950 countsByYear W20678889502013 @default.
• W2067888950 countsByYear W20678889502016 @default.
• W2067888950 countsByYear W20678889502018 @default.
• W2067888950 crossrefType "journal-article" @default.
• W2067888950 hasAuthorship W2067888950A5023680900 @default.
• W2067888950 hasAuthorship W2067888950A5043835524 @default.
• W2067888950 hasAuthorship W2067888950A5054027214 @default.
• W2067888950 hasAuthorship W2067888950A5063335320 @default.
• W2067888950 hasAuthorship W2067888950A5078352037 @default.
• W2067888950 hasConcept C104317684 @default.
• W2067888950 hasConcept C111113717 @default.
• W2067888950 hasConcept C112705442 @default.
• W2067888950 hasConcept C126322002 @default.
• W2067888950 hasConcept C137183658 @default.
• W2067888950 hasConcept C142724271 @default.
• W2067888950 hasConcept C180754005 @default.
• W2067888950 hasConcept C185361966 @default.
• W2067888950 hasConcept C185592680 @default.
• W2067888950 hasConcept C204787440 @default.
• W2067888950 hasConcept C27081682 @default.
• W2067888950 hasConcept C2776976799 @default.
• W2067888950 hasConcept C2777525119 @default.
• W2067888950 hasConcept C2779134260 @default.
• W2067888950 hasConcept C2779734285 @default.
• W2067888950 hasConcept C2780304432 @default.
• W2067888950 hasConcept C2780405171 @default.
• W2067888950 hasConcept C42219234 @default.
• W2067888950 hasConcept C513476851 @default.
• W2067888950 hasConcept C55493867 @default.
• W2067888950 hasConcept C71924100 @default.
• W2067888950 hasConcept C87813604 @default.
• W2067888950 hasConcept C98274493 @default.
• W2067888950 hasConceptScore W2067888950C104317684 @default.
• W2067888950 hasConceptScore W2067888950C111113717 @default.
• W2067888950 hasConceptScore W2067888950C112705442 @default.
• W2067888950 hasConceptScore W2067888950C126322002 @default.
• W2067888950 hasConceptScore W2067888950C137183658 @default.
• W2067888950 hasConceptScore W2067888950C142724271 @default.
• W2067888950 hasConceptScore W2067888950C180754005 @default.
• W2067888950 hasConceptScore W2067888950C185361966 @default.
• W2067888950 hasConceptScore W2067888950C185592680 @default.
• W2067888950 hasConceptScore W2067888950C204787440 @default.
• W2067888950 hasConceptScore W2067888950C27081682 @default.
• W2067888950 hasConceptScore W2067888950C2776976799 @default.
• W2067888950 hasConceptScore W2067888950C2777525119 @default.
• W2067888950 hasConceptScore W2067888950C2779134260 @default.
• W2067888950 hasConceptScore W2067888950C2779734285 @default.
• W2067888950 hasConceptScore W2067888950C2780304432 @default.
• W2067888950 hasConceptScore W2067888950C2780405171 @default.
• W2067888950 hasConceptScore W2067888950C42219234 @default.
• W2067888950 hasConceptScore W2067888950C513476851 @default.
• W2067888950 hasConceptScore W2067888950C55493867 @default.
• W2067888950 hasConceptScore W2067888950C71924100 @default.
• W2067888950 hasConceptScore W2067888950C87813604 @default.
• W2067888950 hasConceptScore W2067888950C98274493 @default.
• W2067888950 hasIssue "9" @default.
• W2067888950 hasLocation W20678889501 @default.

• next